Top

Published in:

01-11-2016 | Review

Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis

Authors: P. Lucato, C. Trevisan, B. Stubbs, B. M. Zanforlini, M. Solmi, C. Luchini, G. Girotti, S. Pizzato, E. Manzato, G. Sergi, S. Giannini, M. Fusaro, N. Veronese

Published in: Osteoporosis International | Issue 11/2016

Abstract

Summary

Our meta-analysis demonstrates that people with nephrolithiasis have decreased bone mineral density, an increased odds of osteoporosis, and potentially an elevated risk of fractures.

Introduction

People with nephrolithiasis might be at risk of reduced bone mineral density (BMD) and fractures, but the data is equivocal. We conducted a meta-analysis to investigate if patients with nephrolithiasis have worse bone health outcomes (BMD), osteoporosis, and fractures versus healthy controls (HCs).

Methods

Two investigators searched major databases for articles reporting BMD (expressed as g/cm² or a T- or Z-score), osteoporosis or fractures in a sample of people with nephrolithiasis, and HCs. Standardized mean differences (SMDs), 95 % confidence intervals (CIs) were calculated for BMD parameters; in addition odds (ORs) for case-control and adjusted hazard ratios (HRs) in longitudinal studies for categorical variables were calculated.

Results

From 1816 initial hits, 28 studies were included. A meta-analysis of case-control studies including 1595 patients with nephrolithiasis (mean age 41.1 years) versus 3402 HCs (mean age 40.2 years) was conducted. Patients with nephrolithiasis showed significant lower T-scores values for the spine (seven studies; SMD = −0.69; 95 % CI = −0.86 to −0.52; I ² = 0 %), total hip (seven studies; SMD = −0.82; 95 % CI = −1.11 to −0.52; I ² = 72 %), and femoral neck (six studies; SMD = −0.67; 95 % CI = −−1.00 to −0.34; I ² = 69 %). A meta-analysis of the case-controlled studies suggests that people with nephrolithiasis are at increased risk of fractures (OR = 1.15, 95 % CI = 1.12–1.17, p < 0.0001, studies = 4), while the risk of fractures in two longitudinal studies demonstrated trend level significance (HR = 1.31, 95 % CI = 0.95–1.62). People with nephrolithiasis were four times more likely to have osteoporosis than HCs (OR = 4.12, p < 0.0001).

Conclusions

Nephrolithiasis is associated with lower BMD, an increased risk of osteoporosis, and possibly, fractures. Future screening/preventative interventions targeting bone health might be indicated.

Available only for authorised users

Masi L (2008) Epidemiology of osteoporosis. Clin Cases Miner Bone Metab 5:11–3PubMedPubMedCentral

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–33. doi:10.1007/s00198-006-0172-4 CrossRefPubMed

Sakhaee K, Maalouf NM, Kumar R et al (2011) Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 79:393–403. doi:10.1038/ki.2010.473 CrossRefPubMed

Melton LJ, Crowson CS, Khosla S et al (1998) Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 53:459–64. doi:10.1046/j.1523-1755.1998.00779.x CrossRefPubMed

Lawoyin S, Sismilich S, Browne R, Pak CY (1979) Bone mineral content in patients with calcium urolithiasis. Metabolism 28:1250–4CrossRefPubMed

Ou S-M, Chen Y-T, Shih C-J, Tarng D-C (2015) Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study. Osteoporos Int 26:1261–9. doi:10.1007/s00198-014-2998-5 CrossRefPubMed

Vosburgh E, Peters TJ (1987) Pathogenesis of idiopathic hypercalciuria: a review. J R Soc Med 80:34–7PubMedPubMedCentral

Giannini S, Nobile M, Dalle Carbonare L et al (2003) Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol 149:209–13CrossRefPubMed

Cerdá Gabaroi D, Peris P, Monegal A et al (2010) Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17:135–9. doi:10.1097/gme.0b013e3181ade8e5 CrossRefPubMed

10.

Thorleifsson G, Holm H, Edvardsson V et al (2009) Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41:926–30. doi:10.1038/ng.404 CrossRefPubMed

11.

Rebsamen MC, Sun J, Norman AW, Liao JK (2002) 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 91:17–24CrossRefPubMed

12.

Trinchieri A (2005) Bone mineral content in calcium renal stone formers. Urol Res 33:247–53. doi:10.1007/s00240-005-0498-y CrossRefPubMed

13.

Fuss M, Pepersack T, Van Geel J et al (1990) Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers. Calcif Tissue Int 46:9–13CrossRefPubMed

14.

Trinchieri A, Nespoli R, Ostini F et al (1998) A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 159:654–7CrossRefPubMed

15.

von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349. doi:10.1016/j.jclinepi.2007.11.008 CrossRef

16.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. doi:10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentral

17.

IQ solutions I bone mass measurement: what the numbers mean

18.

Wells G, Shea B, O’Connell D et al (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. (Available from URL http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) 2012. doi: 10.2307/632432

19.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. doi:10.1016/0197-2456(86)90046-2 CrossRefPubMed

20.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. doi:10.1002/sim.1186 CrossRefPubMed

21.

Sella S, Cattelan C, Realdi G, Giannini S (2008) Bone disease in primary hypercalciuria. Clin Cases Miner Bone Metab 5:118–26PubMedPubMedCentral

22.

Giannini S, Nobile M, Sella S, Dalle Carbonare L (2005) Bone disease in primary hypercalciuria. Crit Rev Clin Lab Sci 42:229–48. doi:10.1080/10408360590913533 CrossRefPubMed

23.

Tasca A, Dalle Carbonare L, Nigro F, Giannini S (2009) Bone disease in patients with primary hypercalciuria and calcium nephrolithiasis. Urology 74:22–7. doi:10.1016/j.urology.2008.11.014 CrossRefPubMed

24.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101. doi:10.2307/2533446 CrossRefPubMed

25.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. doi:10.1136/bmj.316.7129.469 CrossRefPubMedPubMedCentral

26.

Arrabal-Polo MA, Arrabal-Martin M, Girón-Prieto MS et al (2012) Osteopenia/osteoporosis in patients with calcium nephrolithiasis. Urol Res 40:709–716. doi:10.1007/s00240-012-0497-8 CrossRefPubMed

27.

Arrabal-Polo MA, Arrabal-Martin M, Arias-Santiago S (2013) Bone and metabolic markers in women with recurrent calcium stones. Korean J Urol 54:177–182. doi:10.4111/kju.2013.54.3.177 CrossRefPubMedPubMedCentral

28.

Arrabal-Polo MA, Girón-Prieto MS, del Carmen Cano-García M et al (2015) Retrospective review of serum and urinary lithogenic risk factors in patients with osteoporosis and osteopenia. Urology 85:782–785. doi:10.1016/j.urology.2015.01.019 CrossRefPubMed

29.

Asplin JR, Bauer KA, Kinder J et al (2003) Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 63:662–669. doi:10.1046/j.1523-1755.2003.00763.x CrossRefPubMed

30.

Carbone LD, Hovey KM, Andrews CA et al (2015) Urinary tract stones and osteoporosis: findings from the women’s health initiative. J Bone Miner Res 30:2096–2102. doi:10.1002/jbmr.2553 CrossRefPubMed

31.

Celik A, Davutoglu V, Sarica K et al (2010) Relationship between renal stone formation, mitral annular calcification and bone resorption markers. Ann Saudi Med 30:301–305. doi:10.4103/0256-4947.65264 CrossRefPubMedPubMedCentral

32.

Denburg MR, Leonard MB, Haynes K et al (2014) Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 1–8. doi: 10.2215/CJN.04340514

33.

Camille B, Christophe B, Yvon B et al (2012) Electrolyte disorders/nephrolithiasis. Nephrol Dial Transplant 27:ii178–ii181. doi:10.1093/ndt/gfs222 CrossRef

34.

Ghazali A, Fuentès V, Desaint C et al (1997) Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 82:32–8PubMed

35.

Guerra, Angela Nouvenne, Antonio Pedrazzoni, Michele Meschi T (2009) Guerra, 2009 abstract.pdf. In: Eff. body Compos. bone density Heal. Women with idiopathic calcium nephrolithiasis. p 81

36.

Heilberg IP, Martini LA, Szejnfeld VL et al (1994) Bone disease in calcium stone forming patients. Clin Nephrol 42:175–82PubMed

37.

Hekimsoy Z, Biberoglu S, Kazimoglu H et al (2003) Bone mineral density and biochemical markers of bone in patients with idiopathic hypercalciuria. Endocrinologist 13:417–421. doi:10.1097/01.ten.0000089863.23074.23 CrossRef

38.

Jaeger P, Lippuner K, Casez JP et al (1994) Low bone mass in idiopathic renal stone formers: magnitude and significance. 9

39.

Kaste SC, Thomas NA, Rai SN et al (2009) Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia. Leuk Off J Leuk Soc Am Leuk Res Fund UK 23:104–108. doi:10.1038/leu.2008.269 CrossRef

40.

Keller JJ, Lin CC, Kang JH, Lin HC (2013) Association between osteoporosis and urinary calculus: evidence from a population-based study. Osteoporos Int 24:651–657. doi:10.1007/s00198-012-2019-5 CrossRefPubMed

41.

Mete U, Garg PR, Prakash M, Dutta P (2015) Pd4-02 should bone mineral density (BMD) be included in the metabolic evaluation of young adults with calcium kidney stone disease?: a prospective study. J Urol 193:e87. doi:10.1016/j.juro.2015.02.314 CrossRef

42.

Moyano MJ, Tejada MJG De, Lozano RG et al (2007) Alteraciones en el metabolismo mineral óseo en pacientes con urolitiasis de repetición y polimorfismos del gen del receptor de la vitamina D . Resultados preliminares

43.

Pricop C (2014) Particularities of bone metabolism and calcium regulators in a group of young males with idiopathic hypercalciuria and relapsing kidney lithiasis. Acta Endocrinol 10:220–227. doi:10.4183/aeb.2014.220

44.

Weisinger JR, Alonzo E, Bellorin-Font E et al (1996) Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 49:244–250CrossRefPubMed

45.

Wong P, Fuller PJ, Gillespie MT et al (2013) Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 24:1965–71. doi:10.1007/s00198-012-2260-y CrossRefPubMed

46.

Zanchetta JR, Rodriguez G, Negri AL et al (1996) Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron 73:557–560PubMed

47.

Borowy P, Czerwinski E, Gorna A (2011) BMD in postmenopausal women with nephrolithiasis: 5-10-year observations. Osteoporos Int 22(Suppl 1):S218. doi:10.1007/s00198-011-1567-4

48.

Tasca A, Cacciola A, Ferrarese P et al (2002) Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology 59:865–9, discussion 869CrossRefPubMed

49.

Cvijetic S, Füredi-milhofer H, Babic-ivancic V, Tucak A (2002) Bone mineral density loss in patients with urolithiasis: a follow-up study. 33:152–157

50.

Bijelic R, Balaban M, Milicevic S (2015) Gender representation of osteoporosis in patients with urolithiasis. Med Arch (Sarajevo, Bosnia Herzegovina) 69:331–333. doi:10.5455/medarh.2015.69.331-333

51.

Tugcu V, Ozbek E, Aras B et al (2007) Bone mineral density measurement in patients with recurrent normocalciuric calcium stone disease. Urol Res 35:29–34. doi:10.1007/s00240-006-0074-0 CrossRefPubMed

52.

Tsuji H, Umekawa T, Kurita T et al (2005) Analysis of bone mineral density in urolithiasis patients. Int J Urol 12:335–339. doi:10.1111/j.1442-2042.2005.01049.x CrossRefPubMed

53.

Bijelic R, Milicevic S, Balaban J (2014) Incidence of osteoporosis in patients with urolithiasis. Med Arch 68:335. doi:10.5455/medarh.2014.68.335-338 CrossRefPubMedPubMedCentral

54.

Arrabal-Polo MA, Arrabal-Martin M, Arias-Santiago S et al (2012) Metabolic-mineral study in patients with renal calcium lithiasis, severe lithogenic activity and loss of bone mineral density. Singap Med J 53:808–13

55.

Letavernier E, Traxer O, Daudon M et al (2011) Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol 6:1149–54. doi:10.2215/CJN.10191110 CrossRefPubMedPubMedCentral

56.

Tannenbaum C, Clark J, Schwartzman K et al (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431–7. doi:10.1210/jc.2002-020275 CrossRefPubMed

57.

Eller-Vainicher C, Cairoli E, Zhukouskaya VV et al (2013) Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur J Endocrinol 169:225–37. doi:10.1530/EJE-13-0102 CrossRefPubMed

58.

Bordier P, Ryckewart A, Gueris J, Rasmussen H (1977) On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med 63:398–409CrossRefPubMed

59.

Vezzoli G, Rubinacci A, Bianchin C et al (2003) Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis 42:1177–83CrossRefPubMed

60.

Vezzoli G, Arcidiacono T, Paloschi V et al (2008) Update on the genetics of nephrolithiasis. Clin Cases Miner Bone Metab 5:110–3PubMedPubMedCentral

61.

Tebben PJ, Milliner DS, Horst RL et al (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97:E423–7. doi:10.1210/jc.2011-1935 CrossRefPubMedPubMedCentral

62.

Reed BY, Gitomer WL, Heller HJ et al (2002) Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 87:1476–85. doi:10.1210/jcem.87.4.8300 CrossRefPubMed

63.

Geng W, Hill K, Zerwekh JE et al (2009) Inhibition of osteoclast formation and function by bicarbonate: role of soluble adenylyl cyclase. J Cell Physiol 220:332–40. doi:10.1002/jcp.21767 CrossRefPubMedPubMedCentral

64.

Prié D, Beck L, Friedlander G, Silve C (2004) Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization. Curr Opin Nephrol Hypertens 13:675–81CrossRefPubMed

65.

Tsao K-C, Wu T-L, Chang P-Y et al (2007) Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 21:426–31. doi:10.1002/jcla.20215 CrossRefPubMed

66.

Lacey DL, Grosso LE, Moser SA et al (1993) IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 91:1731–42. doi:10.1172/JCI116383 CrossRefPubMedPubMedCentral

67.

Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–83. doi:10.1056/NEJMoa055218 CrossRefPubMed

68.

Heaney RP (2008) Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr 27:519–27CrossRefPubMed

69.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–8. doi:10.1046/j.1523-1755.2001.00746.x CrossRefPubMed

70.

Borghi L, Schianchi T, Meschi T et al (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77–84. doi:10.1056/NEJMoa010369 CrossRefPubMed

71.

Nouvenne A, Meschi T, Guerra A et al (2008) Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab 5:135–41PubMedPubMedCentral

72.

Marckmann P, Osther P, Pedersen AN, Jespersen B (2015) High-protein diets and renal health. J Ren Nutr 25:1–5. doi:10.1053/j.jrn.2014.06.002 CrossRefPubMed

73.

Heaney RP, Layman DK (2008) Amount and type of protein influences bone health. Am J Clin Nutr 87:1567S–1570PubMed

Title: Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis
Authors: P. Lucato
C. Trevisan
B. Stubbs
B. M. Zanforlini
M. Solmi
C. Luchini
G. Girotti
S. Pizzato
E. Manzato
G. Sergi
S. Giannini
M. Fusaro
N. Veronese
Publication date: 01-11-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 11/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3658-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2016

Selective protein depletion impairs bone growth and causes liver fatty infiltration in female rats: prevention by Spirulina alga

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses

Association of 3q13.32 variants with hip trochanter and intertrochanter bone mineral density identified by a genome-wide association study

Systemic markers of microvascular disease and bone mineral density in older adults

Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?

Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis